An excerpt from the article can be found below:
"EMulate Therapeutics Voyager ulRFE® system. It is a non-invasive, non-thermal, non-ionizing, non-sterile medical device, the first of many product expressions of the company's underlying ulRFE platform technology. Showing promise in preclinical and clinical trials, the EMulate Therapeutics Voyager has potential treatment applications in a wide range of diseases, including cancer, chronic pain, and inflammation, among others. EMulate Therapeutics' Voyager device is currently being evaluated to treat glioblastoma multiforme (GBM) brain tumors in human clinical trials.
'The ultimate goal of EMulate Therapeutics is to deliver beneficial effects that would improve life for humans, animals, and other biological organisms without the need for chemicals that may have harmful side effects,' says Chris E. Rivera, President and CEO of EMulate Therapeutics.